Latest News

– If approved by the European Commission, enzalutamide will be the only oral therapy for the treatment of metastatic hormone-sensitive prostate cancer in addition to non-metastatic and metastatic castration-resistant prostate cancer San Francisco, CA (UroToday.com) — Astellas Pharma Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has […]

(UroToday.com) There is variability in the evaluation, treatment, and referral patterns for recurrent urinary tract infections (rUTI). This group sought to analyze patterns in the workup and surgical management of rUTI at their institution. Data collected included demographics, provider specialty, and workup, including the performance of genitourinary exam, urodynamic evaluation, cystoscopy, and imaging and if […]

(UroToday.com) Underactive bladder (UAB) has been under-discussed and under-researched for years, despite the fact it is common, severe, and lacks effective treatment.  It is one of the greatest areas of unmet need and yet has the greatest opportunity for advancement in functional urology. Dr. Christopher Chapple recommended the 2020 review by Mike Chancellor. The etiology of […]

(UroToday.com) Vaginal pessaries are a viable non-surgical treatment option especially as complications associated with mesh used in the surgical treatment of stress urinary incontinence (SUI) are of concern to providers and women.

(UroToday.com) The study’s aim was to show how frailty affects perioperative complications in women undergoing pelvic organ prolapse (POP) surgery. They sought to determine (1) the role of frailty on postoperative complications and (2) the association of racial and socioeconomic differences between frailty and postoperative complications among women undergoing apical prolapse repair.

Diane Newman: Welcome to the UroToday’s Bladder Health Center of Excellence. I’m Diane Newman, the Center’s editor, and here with me today is Professor Hashim Hashim, a world-renowned functional urological surgeon and honorary professor of urology. He is the director of the UK’s most active urodynamics unit located at the Bristol Urological Institute. A site […]

There have been substantial changes in the management of patients with metastatic renal cell carcinoma (mRCC) over the past decade, with upfront immunotherapy-based combinations replacing targeted therapies.

Body composition and inflammation are gaining importance for prognostication in cancer. This study investigated the individual and combined utility of the preoperative skeletal muscle index (SMI) and the modified Glasgow Prognostic Score (mGPS) for estimating postoperative outcomes in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy.

Radium-223 prolongs survival in a fraction of men with bone metastatic prostate cancer (PCa). However, there are no markers for monitoring response and resistance to Radium-223 treatment. Exosomes are mediators of intercellular communication and may reflect response of the bone microenvironment to Radium-223 treatment.

While multi-parametric Magnetic Resonance Imaging (MRI) shows great promise in assisting with prostate cancer diagnosis and localization, subtle differences in appearance between cancer and normal tissue lead to many false positive and false negative interpretations by radiologists.